Global healthcare leader Merck Sharp & Dohme (MSD) yesterday announced a strategic partnership with the country's Healthcare Pharmaceuticals Limited (HPL).
The deal will allow MSD to provide advanced medical services through HPL and it is also expected to bring a special focus on women's health issues, as well as strong scientific knowledge, global experience and unique patient-centric solutions.
“This partnership will allow access to MSD’s best-in-class innovative products and also collaborate for scientific expertise with leading medical institutions and healthcare providers to work towards enhancing patient management and care in Bangladesh,” said KG Ananthakrishnan, president and managing director of MSD in South Asia, during a press briefing.
Three vaccination programmes have already been launched under the partnership – one of them an advanced vaccination to prevent cervical cancer.
The partnership further aims to build various customised services, such as an app that will help measure and identify diabetes during Ramadan for Type II Diabetes patients.
“Although this is just the beginning of the partnership, MSD’s interest is to continue this as a long-term deal in providing service to patients as well as help in research on different health areas,” Ananthakrishnan said.
MSD is a global healthcare leader which operates in more than 140 countries and provides services through their prescription medicines, vaccines, biologic therapies and animal health products.